Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Jaguar Health, Inc. issued common stock to Institutional Investor.
- Security
- common stock
- Purchaser
- Institutional Investor
Exact text from the filing
In consideration for the Institutional Investor’s execution and delivery of the ELOC Agreement, the Company agreed to issue to the Institutional Investor on the effective date of the ELOC Registration Statement (as defined hereunder) $800,000 worth of the Company’s Common Stock, valued at the VWAP Purchase Price as of such effective date (the “Commitment Shares”).
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Jaguar Health, Inc.: Filed Series P Certificate of Designation with Delaware Secretary of State on June 8, 2026, effective upon filing, authorizing up to 300 shares of Series P Preferred Stock with specific dividend, voting, and liquidation preferences (effective 2026-06-08).
- Change
- charter amendment
- Effective
- 2026-06-08
Exact text from the filing
The preferences, rights, limitations and other matters relating to the Series P Preferred Stock are set forth in the Certificate of Designation, which the Company filed with the Secretary of State of the State of Delaware on June 8, 2026. The Certificate of Designation became effective with the Secretary of State of the State of Delaware upon filing. The Certificate of Designation authorizes the Company to issue up to 300 of its 4,475,074 authorized shares of preferred stock as Series P Preferred Stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Jaguar Health, Inc. entered into common stock purchase agreement with an accredited investor valued at up to an aggregate of $40 million (effective 2026-06-09).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- an accredited investor
- Value
- up to an aggregate of $40 million
- Effective
- 2026-06-09
Exact text from the filing
On June 9, 2026, Jaguar Health, Inc. (the “Company”) entered into a common stock purchase agreement (the “ELOC Agreement”) with an accredited investor (the “Institutional Investor”), which provides that, upon the terms and subject to the conditions set forth therein, the Institutional Investor is committed to purchase up to an aggregate of $40 million of shares of Common Stock.
View on SEC.gov